MaxCyte, Inc. Director Dealings and Issue of Equity (6562P)
February 19 2021 - 1:00AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 6562P
MaxCyte, Inc.
19 February 2021
MaxCyte, Inc.
("MaxCyte" or the "Company")
Director Dealings and Issue of Equity
Total Voting Rights
Gaithersburg, Maryland - 19 February 2021: MaxCyte (LSE: MXCT,
MXCL, MXCN), the global cell-based medicines and life sciences
company, announces that Will Brooke, Non-Executive Director of the
Company, has exercised options over 40,900 shares of common stock,
$0.01 par, of the Company ("Common Stock") ("Exercise"). The 40,900
new shares of Common Stock issued pursuant to the Exercise ("New
Common Stock") have been sold by Mr Brooke at a price of 1015 pence
per Common Stock ("Sale").
Following the Exercise and Sale, Mr Brooke's holding of Common
Stock remains unchanged at a total of 50,302 Common Stock,
representing 0.1% of the issued share capital of the Company. Mr
Brooke holds a further 128,500 options over Common Stock.
Total voting rights
The new Common Stock will be allocated out of the common stock
the subject of the block listing announced on 2 May 2017. The New
Common Stock will rank pari passu with the existing shares of
common stock of the Company. The total issued stock capital of the
Company following the issue of the New Common Stock and following
the recent issue of an additional 597,877 new Common Stock to
non-PDMRs in satisfaction of the exercise of share options, is
84,555,946 shares of common stock. Shareholders in the Company may
use this figure as the denominator for the calculations by which
they will determine if they are required to notify their interest
in, or a change to their interest in, the stock capital of the
Company.
The number of unrestricted shares of Common Stock trading under
the symbol 'MXCT' is 74,325,857 ; the number of restricted shares
of Common Stock trading under the symbol 'MXCL' is 9,900,089 a nd
the number of restricted shares of Common Stock trading under the
symbol 'MXCN' will be 330,000.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014 ("MAR").
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Will Brooke
=============================== ===========================================
2 Reason for the notification
============================================================================
a) Position/status Non Executive Director
=============================== ===========================================
b) Initial notification/Amendment Initial notification
=============================== ===========================================
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
============================================================================
a) Name MaxCyte, Inc.
=============================== ===========================================
b) LEI 54930053YHXULRFCU991
=============================== ===========================================
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
============================================================================
a) Description of Exercise of options and Sale of Common
the financial Stock
instrument, type
of instrument
=============================== ===========================================
b) Identification US57777K1060
Code
=============================== ===========================================
c) Nature of the Exercise of options and Sale of Common
transaction Stock by PDMR
=============================== ===========================================
d) Price(s) and volume(s) Price(s) Volume(s)
=============================== ================= ========================
N/A 40,900 (option exercise)
1015 pence 40,900 (sale of common
stock)
=============================== ================= ========================
e) Aggregated information N/A
- Aggregated volume N/A
- Price N/A
=============================== ===========================================
f) Date of the transaction 18 February 2021
=============================== ===========================================
g) Place of the transaction London Stock Exchange, AIM Market (XLON)
=============================== ===========================================
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Accounting Officer +1 301 944 1660
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith +44 (0)20 7260 1000
Joint Corporate Broker
Stifel Nicolaus Europe Limited
Healthcare Investment Banking
Nicholas Moore / Ben Maddison /
Samira Essebiyea
Corporate Broking
Nick Adams +44 (0) 20 7710 7600
About MaxCyte
MaxCyte is a world-leading provider of cell-engineering enabling
technology and is responsible for helping to bring next-generation
cell and gene-editing therapies to life. The Company's technology
is deployed by leading drug developers worldwide, including all of
the top ten global biopharmaceutical companies. MaxCyte licences
have been granted for more than 140 cell therapy programmes, with
more than 100 licensed for clinical use, and the Company has now
entered into twelve clinical/commercial license partnerships with
leading cell therapy and gene editing developers. MaxCyte was
founded in 1998, is listed on the London Stock Exchange (LSE: MXCT,
MXCL, MXCN) and is headquartered in Gaithersburg, Maryland, US. For
more information, visit www.maxcyte.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHTPMBTMTBBTBB
(END) Dow Jones Newswires
February 19, 2021 02:00 ET (07:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2023 to Apr 2024